Lanicemine

Lanicemine

Clinical data
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (1S)-1-Phenyl-2-pyridin-2-ylethanamine
CAS Number	153322-05-5
PubChem CID	9794203
IUPHAR/BPS	7681
ChemSpider	7969970
UNII	9TMU325RK3
Chemical and physical data
Formula	C13H14N2
Molar mass	198.269 g·mol−1
3D model (JSmol)	Interactive image
SMILES N[C@H](C1=CC=CC=C1)CC2=NC=CC=C2
InChI InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1 Key:FWUQWDCOOWEXRY-ZDUSSCGKSA-N

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.

See also

• 4-Chlorokynurenine
• AD-1211
• Apimostinel
• CERC-301
• Diphenidine
• Ephenidine
• Esketamine
• Lefetamine
• Memantine
• Methoxphenidine
• MT-45
• Rapastinel